Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination
Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme · 2023
Read Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination by Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10714663.txt.
Description
Katharina Robichon and co-authors pair a kappa opioid drug with a standard multiple sclerosis drug to fight myelin loss in mice, in work from 2023. Current sclerosis drugs cut relapses but do not halt progression or regrow myelin. Switching on kappa opioid receptors had shown promise for repair.
The team used the standard mouse model of immune attack on myelin. The kappa drug joined one of two standard drugs in turn. With the first partner, mice recovered more and relapsed less than under either drug alone. Immune cell entry into the brain and cord dropped in step. Myelin measures were checked as well. The pair's gains look complementary, not just additive.
Catalog record
| CREATOR | Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |